## 3 Results
### Pairwise Meta-Analysis
\begin{tabular}{c c c c c c} \hline \hline
**Outcome** & **Interruption (vs. Prolonged Sitting)** & **N of Studies** & **N of People** & **Effect Estimates** & \(\mathbf{I^{2}\) (\%)** \\ \hline Type/intensity & & & & & \\ \multirow{4}{*}{Blood glucose} & MVPA & 7 & 147 & \(\mathbf{-0.6\) (\(-0.83\), \(-0.37\))} & \multirow{4}{*}{96.4} \\  & LPA & 18 & 339 & \(\mathbf{-1.45\) (\(-2.32\), \(-0.57\))} & \multirow{4}{*}{97.65} \\  & Standing & 8 & 133 & \(\mathbf{-0.65\) (\(-1.21\), \(-0.09\))} & \multirow{4}{*}{81.24} \\  & RE & 3 & 49 & \(\mathbf{-1.04\) (\(-1.58\), \(-0.49\))} & \multirow{4}{*}{97.65} \\ Insulin & MVPA & 9 & 175 & \(\mathbf{-0.53\) (\(-0.73\), \(-0.32\))} & \multirow{4}{*}{0} \\  & LPA & 15 & 244 & \(\mathbf{-1.04\) (\(-1.53\), \(-0.55\))} & \multirow{4}{*}{85.99} \\  & Standing & 8 & 151 & \(\mathbf{-0.45\) (\(-0.97\), \(0.66\))} & \multirow{4}{*}{80.37} \\  & RE & 2 & 37 & \(\mathbf{-0.86\) (\(-1.34\), \(-0.39\))} & \multirow{4}{*}{74.51} \\ Triacylglycerolglycerol & MVPA & 3 & 90 & \(\mathbf{0.22\) (\(-0.07\), \(0.52\))} & \multirow{4}{*}{75.46} \\  & LPA & 8 & 182 & \(\mathbf{-0.39\) (\(-0.85\), \(0.06\))} & \multirow{4}{*}{81.46} \\  & Standing & 5 & 118 & \(\mathbf{0.42\) (\(0.17\), \(0.68\))} & \multirow{4}{*}{0} \\  & RE & 1 & 24 & \(\mathbf{-0.67\) (\(-1.24\), \(-0.1\))} & \multirow{4}{*}{/} \\ \hline Duration of breaks & & & & & \\ \multirow{4}{*}{Blood glucose} & More than 5 min & 3 & 57 & \(\mathbf{-1.12\) (\(-1.51\), \(-0.73\))} & \multirow{4}{*}{32.82} \\  & 5 min & 4 & 129 & \(\mathbf{-0.99\) (\(-1.53\), \(-0.45\))} & \multirow{4}{*}{83.49} \\  & 3 min & 5 & 87 & \(\mathbf{-0.88\) (\(-1.31\), \(-0.46\))} & \multirow{4}{*}{96.69} \\  & 2 min & 15 & 170 & \(\mathbf{-0.85\) (\(-1.31\), \(-0.39\))} & \multirow{4}{*}{78.82} \\ Insulin & More than 5 min & 4 & 79 & \(\mathbf{0.04\) (\(-0.27\), \(0.34\))} & \multirow{4}{*}{0} \\  & 5 min & 4 & 129 & \(\mathbf{-1.07\) (\(-1.66\), \(-0.49\))} & \multirow{4}{*}{85.87} \\  & 3 min & 3 & 35 & \(\mathbf{-0.91\) (\(-1.35\), \(-0.48\))} & \multirow{4}{*}{58.32} \\ Triacylglycerolglycerol & 2 min & 14 & 215 & \(\mathbf{-0.87\) (\(-1.25\), \(-0.50\))} & \multirow{4}{*}{72.66} \\ Triacylglycerolglycerol & More than 5 min & 3 & 59 & \(\mathbf{-0.24\) (\(-0.6\), \(0.12\))} & \multirow{4}{*}{50.38} \\  & 5 min & 2 & 82 & \(\mathbf{-0.02\) (\(-0.3\), \(0.26\))} & \multirow{4}{*}{91.81} \\  & 3 min & 2 & 35 & \(\mathbf{-0.39\) (\(-0.81\), \(0.02\))} & \multirow{4}{*}{0} \\  & 2 min & 5 & 131 & \(\mathbf{-0.1\) (\(-0.35\), \(0.14\))} & \multirow{4}{*}{82.63} \\ \hline \hline \end{tabular} 
\begin{tabular}{c c c c c} \hline \hline
**Outcome** & **Interruption (vs. Prolonged Sitting)** & **N of Studies** & **N of People** & **Effect Estimates** & \(\mathbf{I^{2}\) (\%)** \\ \hline Type/intensity & & & & \\ \multirow{4}{*}{Blood glucose} & MVPA & 7 & 147 & \(\mathbf{-0.6\) (\(-0.83\), \(-0.37\))} & \multirow{4}{*}{30.91} \\  & LPA & 18 & 339 & \(\mathbf{-1.45\) (\(-2.32\), \(-0.57\))} & \multirow{4}{*}{96.4} \\  & Standing & 8 & 133 & \(\mathbf{-0.65\) (\(-1.21\), \(-0.09\))} & \multirow{4}{*}{81.24} \\  & RE & 3 & 49 & \(\mathbf{-1.04\) (\(-1.58\), \(-0.49\))} & \multirow{4}{*}{97.65} \\ Insulin & MVPA & 9 & 175 & \(\mathbf{-0.53\) (\(-0.73\), \(-0.32\))} & \multirow{4}{*}{0} \\  & LPA & 15 & 244 & \(\mathbf{-1.04\) (\(-1.53\), \(-0.55\))} & \multirow{4}{*}{85.99} \\  & Standing & 8 & 151 & \(\mathbf{-0.45\) (\(-0.97\), \(0.06\))} & \multirow{4}{*}{80.37} \\  & RE & 2 & 37 & \(\mathbf{-0.86\) (\(-1.34\), \(-0.39\))} & \multirow{4}{*}{74.51} \\ Triacylglycerolglycerol & MVPA & 3 & 90 & \(\mathbf{0.22\) (\(-0.07\), \(0.52\))} & \multirow{4}{*}{75.46} \\  & LPA & 8 & 182 & \(\mathbf{-0.39\) (\(-0.85\), \(0.06\))} & \multirow{4}{*}{81.46} \\  & Standing & 5 & 118 & \(\mathbf{0.42\) (\(0.17\), \(0.68\))An interruption greater than 5 min resulted in a significant decrease in glucose but not insulin or triacylglycerollogycerol (Table 2).